穿心莲内酯胶囊治疗上呼吸道感染致咽喉肿痛的临床疗效

Clinical effect of andrographolide capsules in the treatment of sore throat caused by upper respiratory tract infection

目的 观察穿心莲内酯胶囊治疗上呼吸道感染(URTI)致咽喉肿痛的临床疗效。方法 选取2019年8月—2021年8月龙岩市第二医院收治的URTI致咽喉肿痛患者108例,按照随机数字表法分为罗红霉素组与穿心莲组,各54例。罗红霉素组予以罗红霉素胶囊,穿心莲组予以穿心莲内酯胶囊,2组均连续用药7 d。比较2组临床疗效、治疗前后临床症状积分,咽喉肿痛消失时间,治疗前后血清炎性因子[肿瘤坏死因子-α(TNF-α)、白介素-10(IL-10)、降钙素原(PCT)],不良反应。结果 穿心莲组临床总有效率(96.30%)高于罗红霉素组(75.93%)(χ^(2)=9.368,P=0.002)。治疗7 d后,2组临床症状积分低于同组治疗前,且穿心莲组较罗红霉素组低(P<0.01)。穿心莲组咽喉肿痛消失时间为(2.47±0.50)d,短于罗红霉素组的(4.81±0.99)d(t=15.504,P<0.001)。治疗7 d后,2组血清TNF-α、IL-10、PCT水平低于同组治疗前,且穿心莲组较罗红霉素组低(P<0.01)。穿心莲组不良反应总发生率(5.56%)与罗红霉素组(3.70%)比较,差异无统计学意义(P=1.000)。结论 穿心莲内酯胶囊可更有效地缓解URTI致咽喉肿痛患者咽喉痛等症状,抑制炎性递质释放,且不良反应发生率较低,患者接受度较强。

Objective To analyze the clinical effect of andrographolide capsules in the treatment of sore throat caused by upper respiratory tract infection(URTI). Methods A total of 108 cases of patients with sore throat caused by URTI were selected from August 2019 to August 2021 in the Second Hospital of Longyan, which were divided into roxithromycin group and andrographolide group according to the random number table method, with 54 cases in each group. The roxithromycin group was given roxithromycin capsules and the andrographolide group was given andrographolide capsules, both groups were treated continuously for 7 days. Clinical effect, clinical symptom scores, serum inflammatory factors(TNF-α, IL-10, PCT) before and after treatment, the disappearance time of sore throat were compared between the two groups, and the incidence of adverse reactions were observed. Results The clinical total effective rate of andrographolide group(96.30%) was higher than that of roxithromycin group(75.93%)(χ^(2)=9.368, P=0.002). After treatment of 7 days, the clinical symptom scores of the two groups were lower than those of the same group before treatment, and that of andrographolide group was lower than roxithromycin group(P<0.01). The disappearance time of sore throat in andrographolide group was(2.47±0.50) d, which was shorter than(4.81±0.99) d of the roxithromycin group(t=23.154, P<0.001). After treatment of 7 days, the serum TNF-α, IL-10 and PCT levels of the two groups were lower than those of the same group before treatment, and those of andrographolide group were lower than roxithromycin group(P<0.01). The total incidence of adverse reactions in the andrographolide group(5.56%) was not significantly different from that in the roxithromycin group(3.70%)( P=1.000). Conclusion Andrographolide capsules can more effectively alleviate the symptoms of sore throat caused by URTI, inhibit the release of inflammatory transmitters, and the incidence of adverse reactions is low, and the acceptance of patients is strong.